Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.

British journal of haematology - 1 Apr 2021

Claudiani Simone, Apperley Jane F, Szydlo Richard, Khan Afzal, Nesr George, Hayden Chloe, J Innes Andrew, Dominy Kathy, Foskett Pierre, Foroni Letizia, Khorashad Jamshid, Milojkovic Dragana

Abstract excerpt

Targeted therapy for chronic myeloid leukaemia (CML) has allowed for a near-normal patient life-expectancy; however, quality of life and aggravation of existing co-morbidities have posed new treatment challenges. In clinical practice, TKI dose reduction occurs frequently, often on multiple occasions, because of intolerance. We conducted a retrospective 'real-world practice' review of 246 patients receiving lower...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Nitriles

Share to Quinolines

Share to Remission Induction

Share to Safety

Source

Identifiers

PMID: 33368155
DOI: 10.1111/bjh.17286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.PMID 33368155Read ↗

Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity Read ↗

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?Semantic proximity Read ↗

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.Semantic proximity Read ↗

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate.Semantic proximity Read ↗

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.Semantic proximity Read ↗

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.Semantic proximity Read ↗

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitorsSemantic proximity Read ↗

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.Semantic proximity Read ↗

Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.Semantic proximity Read ↗

Beyond Disease Control in Chronic Myeloid Leukemia: Real-World Quality of Life Across TKIs and Treatment-Free RemissionSemantic proximity Read ↗

Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.Semantic proximity Read ↗

Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.